Le cancer séreux de haut gradede l’ovaire en 2018 : avancéeset controverses [High grade serous ovarian cancer 2018 : advances and controversies]

Details

Serval ID
serval:BIB_6BE8EAED562C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Le cancer séreux de haut gradede l’ovaire en 2018 : avancéeset controverses [High grade serous ovarian cancer 2018 : advances and controversies]
Journal
Revue medicale suisse
Author(s)
Mederos N., Wolfer A., Mathevet P., Zaher M., Sarivalasis A.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
16/05/2018
Peer-reviewed
Oui
Volume
14
Number
607
Pages
1037-1041
Language
french
Notes
Publication types: English Abstract ; Journal Article
Publication Status: ppublish
Abstract
The primary treatment of ovarian cancer consists in a complete surgical debulking followed by adjuvant chemotherapy combining platinum with taxanes. Despite this treatment, patient survival has remained stable over the last 20 years. Recently, advances in the sequence, regimens, and route of administration of treatment have enhanced effectiveness and reduced toxicity. Targeted anti-angiogenic therapy and recently PARP inhibitors are now complementing standard treatment and have improved patient progression-free survival. The development of immunotherapy, alone or in combination, brings new perspectives for the future treatment of ovarian cancer.
Pubmed
Create date
17/05/2018 17:50
Last modification date
20/08/2019 15:26
Usage data